CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

Analysis of Bioanalytical Services Market

Analysis of Bioanalytical Services...

Trudiagnostic Unveils Truage PACE For Tracking Biological Aging Rate

Trudiagnostic Unveils Truage PACE For...

Know More About the Comprehensive Bioanalytical Testing Services

Know More About the Comprehensive...

Ways Bioanalytical Laboratory Automation Boosts Efficiency and Accuracy

Ways Bioanalytical Laboratory...

Analytics' Role in Pharmaceutical Success

Analytics' Role in Pharmaceutical...

Discovering and developing drugs using bioanalysis

Discovering and developing drugs...

Developing Next-Generation Technologies for a Better Tomorrow

Developing Next-Generation...

Why Outsource Bioanalysis Work?

Why Outsource Bioanalysis Work?

BetterLife- Carleton University Research Team Secures Funding form Mitacs

Life Sciences Review | Wednesday, May 18, 2022
Tweet

Dr. Argel Aguilar-Valless and his team will collaborate with BetterLife to examine TD-010 in both in vitro and in vivo models developed in their lab as part of the research agreement.


FREMONT, CA: BetterLife Pharma, an emerging biotech company focused on developing compounds to treat neurological conditions, recently announced that the Accelerate program at Mitacs has funded its joint application with Carleton University’s Department of Neuroscience’s Dr. Argel Aguilar-Valles for research into the anxiol.


BetterLife is developing TD-010, also known as dihydrohonokiol-B (DHH-B), as a treatment for benzodiazepine addiction and anxiety. It is a derivative of the anxiolytic substance honokiol, which has shown in animal experiments to have more strong anxiolytic-like effects than the parent drug.


Dr. Ahmad Doroudian, Chief Executive Officer of BetterLife, stated: “TD-010 is a potential novel therapy to treat debilitating anxiety disorders that show resistance to benzodiazepine and other therapies or require a long-term use and therefore put patients at risk for dependency. 


BetterLifes goal is to bring this treatment to the Investigational New Drug (IND) application and the clinic as soon as possible because it is non-addictive yet potentially highly effective. We thank Mitacs for the funding and Carleton University’s team, headed by Dr. Argel Aguilar-Valles at the Department of Neuroscience, for being an ideal partner to help us realize this vision.”


Dr. Argel Aguilar-Valless and his team will collaborate with BetterLife to examine TD-010 in both in vitro and in vivo models developed in their lab as part of the research agreement. Understanding the molecular pathways that underpin psychiatric and neurodevelopmental problems is one of the team’s specialties. Biochemistry, molecular biology, neuronal culture, and animal models are used to accomplish this.


Dr. Argel Aguilar-Valles commented: “We are delighted to have the opportunity to examine TD-010 in our established animal anxiety models. The high rate of resistance to benzodiazepine and SSRIs for chronic anxiety disorder indicates an urgent unmet need for alternative anxiolytic treatments. TD-010 has shown to have more potent anxiolytic effects than its parent compound honokiol and it can be a promising alternative in the treatment of chronic anxiety.”


Weekly Brief

loading
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/betterlife-carleton-university-research-team-secures-funding-form-mitacs-nwid-471.html